Here, we resolve this apparent paradox and demonstrate that the sustained activation of epithelial-intrinsic—rather than stromal—TGFβ signalling acts as a tumour promoter in the intestinal epithelium, driving gene expression programmes associated with aggressive CRC subtypes, which can be exploited therapeutically. Here, TGFB1 is linked to colorectal carcinoma.